Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
Iron Overload Case Library II, Case 2: Adjusting Chelator Dose in Response to Adverse Events in a Patient with Sickle Cell Disease
Many patients with sickle cell disease receive episodic and chronic red blood cell transfusions to prevent stroke and manage sequelae, such as acute anaemia, acute chest syndrome, and vaso-occlusive crises. While most clinicians know when to start chelation therapy in multitransfused patients to prevent iron overload, many clinicians are not sure how to maintain patients on therapy in response to adverse events. Join Mariane deMontalembert, MD as she follows the case of a multitransfused 14-year-old boy with sickle cell disease and demonstrates how to monitor for adverse events and adjust dosage or temporarily interrupt treatment, as needed.
|
|
Faculty
|
|
|
Mariane de Montalembert, MD
Service de Pédiatrie
Hospital Necker
Paris, France
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply knowledge of chelator dose adjustment to manage adverse effects while also maintaining efficacy in patients with sickle cell disease with posttransfusional iron overload.
|
Disclosure Information
Mariane de Montalembert, MD, is on the advisory board for Novartis Pharmaceuticals Corporation. Dr. de Montalembert has disclosed that she will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
